Moderna’s coronavirus vaccine appears to be safe and effective in an early trial where the vaccine evoked some immune response to the virus; however, whether that immune response is enough to protect someone from the coronavirus is still up in the air.
Modern’s chief medical officer Tal Zaks says although the degree to which the vaccine confers immunity will become clear in subsequent tests. Zaks said the levels of protective antibodies produced in the trial were similar to those found in patients who had recovered from the infection, suggesting that the vaccine may provide the same protection as normal, innate immunity.
In the trial, 45 participants were tested. They were divided in three groups, one that received a high dose, one a medium dose, and one a low dose, and all the participants showed evidence of an immune response.